Gaps found in gray areas like adverse events reported on blogs and interactive web events
As the FDA focuses more of its attention on post-marketing surveillance for adverse events (AE), a new study shines light on the reporting practices of some of the largest biopharmaceutical companies in the US.
Best Practices LLC, a research and consulting company, surveyed drug safety executives from 15 biopharmaceutical companies, including Amgen, Boehringer Ingelheim, Novartis, Novo Nordisk and Takeda, on a variety of topics related to post-marketing surveillance of adverse drug events. Best Practices says the study’s objective was to “identify best practices for post-marketing surveillance within the United States, as well as the processes for assessing reports of adverse events, follow-up activities and compliance training.”
Among the findings:
The report, entitled “Best Practices for Post-Marketing Surveillance of Adverse Events within the US,” is available at www.best-in-class.com.
Protecting Temperature-Sensitive Pharmaceuticals, Without Unnecessary Plastic Waste
March 24th 2025Advances in the life sciences are driving a significant increase in the number of temperature-sensitive pharmaceuticals. The packaging industry is meeting the moment with advances of its own, including high-performance, environmentally-friendly materials that allow life science companies meet stringent thermal requirements and ambitious CO2e reduction goals. In this episode, TemperPack’s CEO Peter Wells shares insights from working with life sciences to move to certified biobased, home compostable, and curbside recyclable shipping solutions.